Levobren (Levosulpiride)

Levosulpiride acts as a selective antagonist of dopamine D2 (and D3) receptors in the brain, reducing excessive dopaminergic activity that contributes to psychosis and certain depressive states. In the gut, D2 blockade increases acetylcholine release, facilitating gastric emptying and providing a prokinetic effect.

The specific dose of Levobren is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosage may differ for psychiatric versus gastrointestinal indications and is adjusted according to individual therapeutic needs.

Safety data for levosulpiride in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To order Levobren, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levobren (levosulpiride) differs from many typical antipsychotics by having a relatively selective D2 antagonism and additional prokinetic activity, which can be advantageous for patients with co‑existing gastrointestinal symptoms. Compared with broader‑spectrum agents, it may present a lower risk of metabolic side effects but still carries extrapyramidal risk.

Levobren must be stored at 2‑8 °C, kept refrigerated, protected from light, and should not be frozen or shaken. Maintain the product in its original packaging until use to preserve stability and ensure proper handling during transport.

Levobren is supplied as an injectable solution and can be administered either intramuscularly or intravenously by a qualified healthcare professional. The route, rate, and volume of injection are determined by the prescriber according to the therapeutic indication.

Serious risks include neuroleptic malignant syndrome, severe extrapyramidal reactions such as tardive dyskinesia or acute dystonia, and cardiac arrhythmias like QT prolongation. Prompt medical attention is required if symptoms such as high fever, muscle rigidity, or irregular heartbeats occur.

Levobren is contraindicated in patients with known hypersensitivity to levosulpiride or any component of the formulation. Caution is advised for individuals with severe renal or hepatic impairment, uncontrolled cardiac disease, or a history of neuroleptic malignant syndrome. It should also be avoided in pregnant or breastfeeding women unless absolutely necessary.